CEA联合ROMA指数在卵巢癌患者临床诊断中的价值研究  

The Clinical Diagnostic Value of CEA Combined with ROMA Index in Patients with Ovarian Cancer

作　　者：柏玉 周万青[1] 杨平[1] 高硕[1] BAI Yu;ZHOU Wanqing;YANG Ping;GAO Shuo(Department of Clinical Laboratory,Gulou Hospital,School of Medicine,Nanjing University,Nanjing 210008,China)

机构地区：[1]南京大学医学院附属鼓楼医院检验科,江苏南京210008

出　　处：《标记免疫分析与临床》2024年第10期1832-1835,共4页Labeled Immunoassays and Clinical Medicine

基　　金：国家自然科学基金青年项目(编号:82202600)。

摘　　要：目的探究CEA联合ROMA指数在卵巢癌诊断中的临床价值。方法选取南京鼓楼医院2023年1月份至2024年4月份收治的58例卵巢癌患者作为疾病组,收集同期临床诊治的44例卵巢囊肿患者和58例健康体检女性分别作为疾病对照组和健康对照组,分别检测3组人群CEA和ROMA指数。统计分析3组人群CEA和ROMA指数水平差异性,同时统计分析疾病组不同分期血清CEA、ROMA指数及疾病组不同年龄组间CEA、ROMA指数结果差异性。通过绘制ROC曲线,分析CEA联合ROMA指数对卵巢癌的诊断效能。结果疾病组CEA[1.21(0.83,1.86)U/mL]和疾病对照组CEA[1.85(1.36,2.42)U/mL]均高于健康对照组[0.89(0.61,1.43)U/mL],差异有统计学意义(P<0.05);疾病组ROMA指数[10.79(6.03,26.16)%]高于疾病对照组[8.84(6.50,11.60)%]和健康对照组[7.14(5.51,8.88)%],与健康对照组间差异有统计学意义(P<0.001);疾病对照组的CEA、ROMA指数均高于健康对照组,差异有统计学意义(P<0.05)。卵巢癌组晚期III+IV期患者CEA[1.41(0.87,1.91)U/mL]和ROMA指数[17.07(9.31,41.01)%]均高于早期I+II期患者CEA[1.09(0.72,1.61)U/mL]和ROMA指数(6.04(4.06,11.29)%),ROMA指数之间的差异有统计学意义(P<0.05)。绝经后的卵巢癌患者CEA[1.54(1.18,2.77)U/mL]和ROMA指数[19.17(9.96,41.50)%]均高于绝经前的卵巢癌患者CEA[0.93(0.70,1.20)U/mL]和ROMA指数[6.12(4.21,9.48)%],差异有统计学意义(P<0.001)。经ROC曲线分析,CEA、ROMA指数单独诊断卵巢癌的曲线下面积(AUC)分别为0.658、0.698,灵敏度分别为70.7%、63.8%,特异性分别为53.4%、79.3%;CEA和ROMA指数联合诊断时的曲线下面积(AUC)为0.722,灵敏度和特异性分别为96.6%和48.3%。结论CEA、ROMA指数可作为卵巢癌筛查指标,两者联合筛查灵敏度更高。Objective To evaluate the clinical value of CEA combined with ROMA index in the diagnosis of ovarian cancer.Methods Fifty-eight ovarian cancer patients admitted to Nanjing Gulou Hospital from January,2023 to April,2024 were selected as the disease group,while 44 patients with ovarian cysts and 58 healthy women undergoing physical examinations during the same period of time were collected as the disease control group and the healthy control group,respectively.The CEA and ROMA indices of these three groups were detected respectively.The differences in the levels of CEA and ROMA indices among these three groups were statistically analyzed.The differences in the serum CEA and ROMA indices at different stages in the disease group and the results of CEA and ROMA indices among different age groups in the disease group were also statistically analyzed.The diagnostic efficacy of CEA combined with ROMA index for ovarian cancer was evaluated by drawing ROC curves.Results The CEA[1.21(0.83,1.86)U/mL]in the disease group and the CEA[1.85(1.36,2.42)U/mL]in the disease control group were significantly higher than those in the healthy control group[0.89(0.61,1.43)U/mL](P<0.05);The ROMA index in the disease group[10.79(6.03,26.16)%]was significantly higher than that of the disease control group[8.84(6.50,11.60)%]and the healthy control group[7.14(5.51,8.88)%],also with statistically significant differences between them and the healthy control group(P<0.001);The CEA and ROMA indices of the disease control group were significantly higher than those of the healthy control group(P<0.05).CEA[1.41(0.87,1.91)U/mL]and ROMA index[17.07(9.31,41.01)%]were significantly higher in advanced stage III+IV patients than in early stage I+II patients in the ovarian cancer group,and CEA[1.09(0.72,1.61)U/mL]and ROMA index[6.04(4.06,11.29)%]were significantly different(P<0.05).Postmenopausal patients with ovarian cancer had a significant higher CEA[1.54(1.18,2.77)U/mL]and ROMA index[19.17(9.96,41.50)%]than premenopausal patients with ovarian cancer wi

关 键 词：卵巢癌 CEA ROMA指数 卵巢囊肿 

分 类 号：R737.31[医药卫生—肿瘤]